Press Releases

Press Releases

Data pager

1 2

Show:

PageSizeComboBox
	select

2 pages

6-13-2018

Diamyd Medical’s Remygen™ for regeneration of insulin-producing cells approved for clinical trials

5-18-2018

Update regarding the manufacturing of Diamyd^® drug substance

5-16-2018

Swedish MPA approves an additional injection of Diamyd^® in ongoing clinical pilot trial

5-7-2018

Results supporting intralymphatic administration of Diamyd^® published in the Journal of Diabetes Research

4-23-2018

50% enrollment milestone reached in Diamyd Medical’s European Phase II trial

4-5-2018

Results showing GABA’s relevance for diabetes, patent filed by Diamyd Medical and Uppsala University scientist, published in eBioMedicine

3-28-2018

Quarterly Report II 17/18

3-27-2018

Diamyd^® subcutaneously continues to show weaker results than when administered intralymphatically

3-12-2018

Interim report from DIAGNODE-1 shows continued positive clinical course

3-2-2018

Operational update on the diabetes vaccine Diamyd^® and recombinant GAD

© 2016 -

Privacy Policy | Cookie Policy

Share This Page